Mastodon

Belosalic® (Solution, Ointment) Instructions for Use

ATC Code

D07XC01 (Betamethasone in combination with other drugs)

Active Substances

Salicylic acid (USP)

Betamethasone (Rec.INN)

Clinical-Pharmacological Group

A drug with anti-inflammatory and keratolytic action for external use

Pharmacotherapeutic Group

Corticosteroids used in dermatology; corticosteroids in combination with other agents; high-potency corticosteroids in combination with other agents

Pharmacological Action

A combined drug for external use, the action of which is due to its constituent components. It has anti-inflammatory, anti-edematous, anti-allergic, vasoconstrictive, antiproliferative, immunosuppressive, keratolytic, antimicrobial, antifungal, and local hypothermic action. It inhibits the release of inflammatory mediators, prevents the marginal accumulation of neutrophils, reduces inflammatory exudate and cytokine production, and decreases macrophage migration, leading to a reduction in infiltration and granulation processes.

Due to the presence of salicylic acid, it softens the skin, eliminates horny layers, and promotes deeper penetration of the corticosteroid.

The ointment has a water-repellent effect and forms a protective film that protects the skin from external moisture; having a deep fat-saturating effect, it is most suitable for treating patients with dry and fragile skin.

The lotion (solution in a fat-free base) spreads easily on the skin surface, does not stick or dry out hair, does not leave visible marks, and has a cooling effect on the skin.

Indications

Psoriasis; eczema (especially chronic); ichthyosis; limited prurigo with severe lichenification; atopic dermatitis; diffuse neurodermatitis; simple and allergic dermatitis; urticaria; multiform exudative erythema; lichen simplex chronicus (circumscribed neurodermatitis); dermatoses not amenable to treatment with other corticosteroids (especially lichen ruber verrucosus); lichen planus; dyshidrosis of the skin; seborrheic dermatitis.

ICD codes

ICD-10 code Indication
L20.8 Other atopic dermatitis (neurodermatitis, eczema)
L21 Seborrheic dermatitis
L23 Allergic contact dermatitis
L24 Irritant contact dermatitis
L28.0 Lichen simplex chronicus (circumscribed neurodermatitis)
L28.1 Prurigo nodularis
L28.2 Other prurigo
L29 Pruritus
L30.0 Nummular eczema
L30.1 Dyshidrosis [pompholyx]
L40 Psoriasis
L43 Lichen planus
L50 Urticaria
L51 Erythema multiforme
L51.1 Bullous erythema multiforme (Stevens-Johnson syndrome)
L85.0 Acquired ichthyosis
ICD-11 code Indication
9A06.70 Atopic eczema of the eyelids
DA01.13 Erythema multiforme with oral ulceration
EA80.0 Infantile atopic eczema
EA80.1 Childhood atopic eczema
EA80.2 Adult atopic eczema
EA80.Z Atopic eczema, unspecified
EA81.Z Seborrheic dermatitis, unspecified
EA82 Nummular dermatitis
EA83.00 Lichen simplex of vulva
EA83.01 Lichen simplex of male genital organs
EA83.02 Lichen simplex of perianal area
EA83.0Z Lichen simplex of unspecified location
EA85.0 Vesicular dermatitis of hands and feet
EA85.20 Atopic hand eczema
EA90.Z Psoriasis, unspecified
EA91.Z Lichen planus, unspecified type
EB12.Z Erythema multiforme, unspecified
EB13 Stevens-Johnson syndrome or toxic epidermal necrolysis
EB13.0 Stevens-Johnson syndrome
EC90.Z Itching, unspecified
EC91.0 Prurigo nodularis
EC91.Z Prurigo, unspecified
ED50.0 Acquired ichthyosis
EK00.Z Allergic contact dermatitis, unspecified
EK02.Z Irritant contact dermatitis, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Apply a thin layer of Belosalic® to the affected skin areas two to three times daily.

Gently rub the medication into the skin until fully absorbed.

Limit the treatment course to a maximum of three weeks.

For long-term management, reduce application frequency to every other day.

In chronic conditions, continue treatment for a short period after symptoms resolve to prevent relapse.

Select the formulation based on the lesion type: use the ointment for dry, scaly, or lichenified plaques; use the solution for hairy or intertriginous areas.

Avoid application on the face, groin, and axillae unless specifically directed.

Do not use occlusive dressings unless prescribed by a physician for severe, resistant lesions.

Discontinue use and consult a physician if no improvement is observed within one week, or if irritation occurs.

Monitor for signs of skin atrophy, especially with prolonged use.

In pediatric patients over one year of age, use the minimum amount necessary for the shortest effective duration.

Adverse Reactions

Local reactions burning, irritation, dryness, hypopigmentation, skin itching, folliculitis, hypertrichosis, acneiform eruption.

When using occlusive dressings – skin maceration, striae, skin atrophy, secondary infection, miliaria.

With long-term use – skin atrophy, local hirsutism, telangiectasias, purpura, hypopigmentation, hypertrichosis.

Systemic reactions when applied to large areas, systemic manifestations of the side effects of corticosteroids (growth retardation, Cushing’s syndrome, benign intracranial hypertension after treatment cessation, hyperglycemia, glucosuria, hypokalemia, increased blood pressure) or salicylates (pallor, increased fatigue, drowsiness, hyperventilation against the background of tachypnea, nausea, vomiting, hearing impairment, confusion) are possible.

Contraindications

Bacterial, viral, and fungal skin diseases (pyoderma, syphilis, skin tuberculosis, chickenpox, herpes, actinomycosis, blastomycosis, sporotrichosis); post-vaccination skin reactions; perioral dermatitis; rosacea; trophic ulcers due to chronic venous insufficiency; skin tumors (skin cancer, nevus, atheroma, epithelioma, melanoma, hemangioma, xanthoma, sarcoma); pregnancy; lactation period (do not apply to the skin of the breast before feeding); children under 1 year of age; hypersensitivity to betamethasone or salicylic acid.

With caution

Hepatic insufficiency, children (over 1 year of age), long-term therapy, especially with the use of occlusive dressings.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and lactation (do not apply to the skin of the breast before feeding).

Use in Hepatic Impairment

With caution : hepatic insufficiency.

Pediatric Use

Contraindication — children under 1 year of age.

With caution : children (over 1 year of age).

The use of the ointment in children should be as short as possible (danger of systemic absorption of a proportionally larger amount of active components due to the predominance of skin surface area over body weight and insufficient maturity of the epidermis).

Special Precautions

Avoid getting the drug into the eyes; do not apply to the skin near the eyes and on mucous membranes.

Long-term use on the skin of the face is not recommended – the development of rosacea-like dermatitis, perioral dermatitis, skin atrophy, and acne is possible; avoid use in the anogenital area.

The use of the ointment in children should be as short as possible (danger of systemic absorption of a proportionally larger amount of active components due to the predominance of skin surface area over body weight and insufficient maturity of the epidermis).

If signs of allergic reactions or local irritation appear, treatment should be discontinued.

Drug Interactions

Simultaneous use of cosmetic and dermatological agents for acne therapy, products containing ethanol, or medical soap with a pronounced drying effect may, in certain cases, cause skin irritation.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Belupo, Pharmaceuticals & Cosmetics d.d. (Croatia)

Dosage Form

Bottle OTC Icon Belosalic® Ointment for external use 0.05%+3%: tubes 10 g, 15 g, 20 g, 30 g, or 40 g 1 pc., 15 g and 30 g 2 pcs.

Dosage Form, Packaging, and Composition

Ointment for external use white, homogeneous, semi-transparent.

1 g
Betamethasone dipropionate 0.64 mg,
   Equivalent to betamethasone content 0.5 mg
Salicylic acid 30 mg

Excipients : liquid paraffin – 100 mg, white soft paraffin – 869.36 mg.

10 g – aluminum tubes (1) – cardboard packs.
15 g – aluminum tubes (1) – cardboard packs.
15 g – aluminum tubes (2) – cardboard packs.
20 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (2) – cardboard packs.
40 g – aluminum tubes (1) – cardboard packs.

Marketing Authorization Holder

Belupo, Pharmaceuticals & Cosmetics d.d. (Croatia)

Dosage Form

Bottle OTC Icon Belosalic® lotion Topical solution 0.05%+2%: fl. 50 ml or 100 ml with dropper and fl. 20 ml, 50 ml or 100 ml with spray nozzle

Dosage Form, Packaging, and Composition

Topical solution transparent, colorless, viscous, with the smell of isopropanol.

1 g
Betamethasone dipropionate 0.64 mg,
   Equivalent to betamethasone content 0.5 mg
Salicylic acid 20 mg

Excipients : disodium edetate – 0.3 mg, hypromellose – 5 mg, sodium hydroxide – 5 mg, isopropanol – 392 mg, purified water – 577.06 mg.

50 ml – bottles (1) with a dropper – cardboard packs.
100 ml – bottles (1) with a dropper – cardboard packs.
20 ml – bottles with a spray pump mechanism (1) complete with a spray nozzle – cardboard packs.
50 ml – bottles with a spray pump mechanism (1) complete with a spray nozzle – cardboard packs.
100 ml – bottles with a spray pump mechanism (1) complete with a spray nozzle – cardboard packs.

TABLE OF CONTENTS